Nachrichten und Videos - ACTINIUM PHARMACEUTICALS - Seite 2

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial PR Newswire NEW YORK, May 14, 2024 - Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not...

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting PR Newswire NEW YORK, May 13, 2024 - Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey - Improved survival demonstrated with both Iomab-B and Actimab-A in...

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern PR Newswire NEW YORK, May 7, 2024 Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinar Expansion of Iomab-ACT program with commercial CAR-T supported by ongoing MSKCC clinical...

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting PR Newswire NEW YORK, April 18, 2024 -- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute...

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting PR Newswire NEW YORK, April 1, 2024 - The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis - Represents...

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy PR Newswire NEW YORK, March 26, 2024 Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved therapies totaling sales over $3.5 billion in 2023 and cell and gene therapies forecasted to reach over ninety-thousand patients annually by 2030 Iomab-ACT is...

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand PR Newswire NEW YORK, March 11, 2024 Actinium's cyclotron produced Actinium-225 material has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods and has the potential to be significantly lower cost at commercial scale than currently available production methods Proprietary...

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® PR Newswire NEW YORK, Feb. 26, 2024 - Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm...

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® PR Newswire NEW YORK, Feb. 23, 2024 Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in...

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® PR Newswire NEW YORK, Jan. 2, 2024 - Two oral presentations and three poster presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy NEW YORK , Jan. 2, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader...

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation PR Newswire NEW YORK, Dec. 11, 2023 Relapsed or refractory AML patients with TP53 mutation known to have dismal outcomes due to limited effective treatment options Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to...

Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia PR Newswire NEW YORK, Dec. 11, 2023 Oral presentation highlighted Iomab-B improves overall survival in patients with TP53 mutation with active, relapsed or refractory AML Eighth oral presentation of the Phase 3 SIERRA results at ASH continues to build broad exposure for Iomab-B across key medical and scientific communities globally NEW YORK...

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition PR Newswire NEW YORK, Dec. 8, 2023 Oral presentation to highlight Iomab-B's ability to significantly improve overall survival in patients with relapsed or refractory AML with a TP53 mutation Four presentations in total demonstrating the mutation agnostic efficacy potential of Iomab-B and Actimab-A...

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations PR Newswire NEW YORK, Nov. 6, 2023 Actimab-A can target CD33 positive immune suppressing myeloid derived suppressor cells and restore T cell proliferation and effector response Solid tumor MDSC infiltration and uptake of Actimab-A confirmed by SPECT/CT imaging in a humanized non-small cell lung cancer model NEW YORK ,...

Actinium Appoints Lynn Bodarky as Chief Business Officer PR Newswire NEW YORK, Nov. 3, 2023 - Senior leader with proven track record of executing business development and licensing transactions totaling $5 billion at multinational pharmaceutical and biotechnology companies NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named...

Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023 PR Newswire NEW YORK, Nov. 2, 2023 NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe , taking place November 6 – 8, 2023 in Munich, Germany . Actinium is advancing a pipeline of differentiated,...

Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial PR Newswire NEW YORK, Nov. 2, 2023 - Relapsed or refractory AML patients with a TP53 mutation receiving Iomab-B led allogeneic bone marrow transplant had a median Overall Survival of 5.49 months compared to 1.66 months in patients that did not receive...

Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy PR Newswire NEW YORK, Oct. 4, 2023 - Ongoing clinical trial is the first ever to combine targeted radiotherapy conditioning, Iomab-ACT, with CAR-T cell therapy to achieve lymphodepletion along with reduction of cytokine release syndrome and neurotoxicity - Targeted conditioning directed at CD45 has the potential to...

Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting PR Newswire NEW YORK, Sept. 27, 2023 NEW YORK , Sept. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details an abstract accepted for poster presentation at the upcoming Society of Immunotherapy of Cancer (SITC) 38 th Annual Meeting, which will be held in San Diego , November...

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO PR Newswire NEW YORK, Sept. 7, 2023 - Extended follow-up in the Actimab-A + CLAG-M trial showed median overall survival in patients proceeding to bone marrow transplant of 24 months in all patients and 30 months in patients who received prior venetoclax treatment - Actimab-A shown to enhance the anti-leukemic...